ROCIO NARANJO: Open Payments
NPI 1023345998 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$773 in 47 payments from 10 companies in 2025. Trend: 2023 $584 · 2024 $906 · 2025 $773
Food & beverage: $732Education: $41
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 20 | $178 |
| Regeneron Healthcare Solutions, Inc. | 9 | $168 |
| Novartis Pharmaceuticals Corporation | 3 | $80 |
| AstraZeneca Pharmaceuticals LP | 4 | $80 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $76 |
| BioCryst US Sales Co., LLC | 2 | $63 |
| CSL Behring | 3 | $63 |
| Amgen Inc. | 1 | $34 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $14 |
Products named: DUPIXENT, TRELEGY ELLIPTA, TEZSPIRE, NEFFY, ORLADEYO, NUCALA, Haegarda, Xhance.
Industry payments across CA — which companies pay providers there.
